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STATEMENT OF TRANSLATIONAL RELEVANCE 
Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers that, 
when diagnosed at advanced stage, remains incurable. Due to its rarity, its genomic dissection 
has not been comprehensively explored. This multilayer genomic study, considering the 
transcriptome, miRNome and methylome, is the first of its kind and has uncovered genes 
negatively regulated by methylation. Functional annotation enrichment analysis identified the 
JAK/Stat pathway as a specific hallmark of RETM918T-bearing MTCs. In vitro studies with MTC 
cell models point to a RETM918T genetic class-specific proliferative dependency on STAT3 
activity. Remarkably, the inhibition of STAT3 increases the sensitivity of RETM918T-bearing 
MTC cells to the FDA-approved RET inhibitor Vandetanib. This combinational treatment could 
potentially overcome the adverse effects encountered in clinical practice when Vandetanib 





Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and 
the etiology specific to each known susceptibility mutation remains unknown. Exploiting 
multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in 
MTC development.  
Experimental design: We performed genome-wide DNA methylation profiling assessing 
>27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly 
characterized tumors. mRNA and miRNA expression data was available for 33 and 31 tumors, 
respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for 
validation. 
Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration 
of methylation data with mRNA and miRNA expression data identified genes negatively 
regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, 
DKK4, MMP20 and miR-10a, -30a and -200c. The mutation-specific aberrant methylation of 
PLCB2, DKK4 and MMP20 was validated in 25 independent MTCs by bisulfite 
pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway 
involvement in RETM918T MTCs. Immunostaining (IHC) for the active form of signaling effector 
STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with 
RETM918T-bearing tumors (p-value<0.02). Pharmacological inhibition of STAT3 activity 
increased the sensitivity to Vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.  
Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically 
defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target 





 Medullary thyroid carcinoma (MTC) is a malignant tumor of the thyroid gland. It is 
composed of C-cells and accounts for up to 2% of all thyroid cancers (1). Around 25% of MTCs 
arise due to germline mutations in the "rearranged during transfection" (RET) gene as part of 
Multiple Endocrine Neoplasia type 2 syndrome, while the remaining forms are sporadic. The 
genomic landscape of recurrent driver alterations found in sporadic disease seems to be mainly 
restricted to activating mutations affecting the RET (2) or RAS oncogenes (3, 4). There is a 
distinct genotype-phenotype correlation for each of these alterations (3, 5, 6). The RETM918T 
mutation seems to trigger the most aggressive disease, showing poor prognosis with a higher 
prevalence of distant metastases during follow-up (5, 7). MTC cases with advanced disease are 
treated with tyrosine kinase inhibitors (TKIs), such as Vandetanib or Cabozantinib, which have 
shown to have therapeutic benefits. However, many patients suffer secondary toxicities that lead 
to dose reductions or treatment interruption (8, 9). A comprehensive understanding of the 
molecular mechanisms driving the different genetic classes of this disease is required to identify 
new therapeutic opportunities for these patients. 
 High-throughput technologies have already been used to define genomic signatures 
linked to particular driver mutations in cell lines and other thyroid cancer subtypes (10-15), 
uncovering molecular events associated with progression and recurrence. However, data on 
MTC are scarce due to the disease’s low prevalence and, in consequence, the difficulty in 
collecting an informative sample set. On top of that, C-cells represent less than 1% of the 
thyroid gland, and therefore it is very challenging to portray their normal genomic landscape. To 
date, only a handful of studies using mRNA expression arrays have been published, reporting 
that MTC expression profiles are mutation-specific (16-18). Interestingly, the over-expression 
of genes related to the tumor growth factor beta pathway (17) and tumor invasion and 
metastases (16, 18) were notable among MTCs caused by the RETM918T mutation. On the other 
hand, the miRNA profiling studies published so far have focused on patient outcomes rather 
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than on genetic subtypes of the disease, but have nevertheless uncovered some molecular events 
related to metastasis and worse outcomes (19-21). 
Some of the differentially expressed genes identified in the previous profiling studies 
are undoubtedly regulated by aberrant methylation. However, explorations of this epigenetic 
mechanism in MTC, the deregulation of which is a well-known hallmark of cancer, have been  
limited, either focused on specific candidate genes, such as RAS association domain family 
protein 1 (RASSF1) (22) and Sprouty 1 (SPRY1) (23), or exploring the whole methylome in very 
few samples (15). Thus, it remains poorly characterized.  
Therefore, we studied the role of aberrant DNA methylation in the pathology of genetic 
subtypes of MTC. We quantitatively profiled the largest cohort of medullary thyroid carcinomas 
published to date, composed of 48 samples, based on the DNA methylation levels of >27,000 
CpGs across the genome. We observed significant differences between the methylation patterns 
among the samples carrying distinct mutations. Taking advantage of multilayer genomic data 
consisting of the transcriptome, miRNome and methylome, we uncovered genes negatively 
regulated by methylation. Moreover, pathway enrichment analysis underscored JAK/Stat 
pathway involvement in the RETM918T-driven tumors. Using a series of 101 formalin-fixed 
paraffin-embedded (FFPE) MTC samples, we observed that phosphorylation of the JAK/Stat 
pathway effector STAT3 (Tyr705) was more evident among RETM918T-positive tumors. In vitro 
pharmacological inhibition of STAT3 phosphorylation in two human MTC cell lines (MZ-CRC-
1 and TT) revealed a higher dependency of the RETM918T-mutated MZ-CRC-1 cell line on 
STAT3 signaling. Further, we observed an apparently synergistic effect between the action of 
STAT3 inhibitor and Vandetanib, which could be exploited to treat MTC patients.  
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MATERIALS AND METHODS 
Human MTC tissue samples 
Forty-eight fresh frozen MTC tumor samples were collected at the Spanish National 
Cancer Research Center (CNIO) in collaboration with the CNIO Tumor Bank. Written informed 
consent was obtained from all study participants and the study was approved by the relevant 
institutional review board (Comité de bioética y bienestar animal of the Instituto de Salud 
Carlos III). Sections of each sample were evaluated by a pathologist. Only samples in which at 
least 80% of cells were cancerous were used in this study, and cases with high amyloid content 
were excluded. A total of 101 paraffin-embedded (FFPE) MTC samples from unrelated 
individuals were used for validation studies. Twenty-five were used for the validation of DNA 
functional methylation markers, and the entire collection was used for an immunohistochemical 
study. Hematoxylin and eosin stained sections of each FFPE tumor sample were examined by a 
pathologist to select MTC areas representative of each tumor and these were used to construct 
tissue microarrays (TMA). Three TMAs containing 2 cores from each of 94 tumor samples were 
constructed. The remaining 7 tumors were evaluated as complete sections. 
Cell lines and culture conditions 
MZ-CRC-1 and TT cell lines were provided by Dr. James Fagin (Human Oncology & 
Pathogenesis Program, Memorial Sloan Kettering Cancer Centre, New York, USA) and 
authenticated by RET sequencing. The MZ-CRC-1 cell line is derived from a metastatic MTC 
and harbors the RETM918T mutation, while TT cell line harbors a mutation in the 634th codon of 
RET. MZ-CRC-1 and TT were cultured in Dulbecco’s modified Eagle medium GlutaMAX 
(DMEM, Invitrogen) and F12 Nut Mix medium with GlutaMAX (Invitrogen), respectively, 
supplemented with 10% (v/v) fetal bovine serum (FBS, PAA laboratories), 1% (v/v) 
penicillin/streptomycin and 0.6% (v/v) Fungizone (Gibco).  
DNA, RNA and protein extraction 
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Genomic DNA from all samples (frozen and FFPE tumors and cell lines) was extracted 
using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s protocol. 
Total RNA was extracted from 5x106 of MZ-CRC-1 and TT cells and 1 ml of TRIzol® (Life 
Technologies) using the standard conditions. For immunoblotting, cells lysates were produced 
in RIPA lysis buffer (Sigma) containing protease inhibitor mixture (Sigma) and Phosphatase 
Inhibitor Cocktail 2&3 (Sigma). 
Mutation analysis 
 All samples were screened for hotspot mutations in exons 8, 10, 11, 13, 14, 15 and 16 of 
RET by Sanger sequencing. If negative, the hotspot codons 12, 13 and 61 of exons 2 and 3 of all 
RAS genes were screened using the same technique. Primer sequences and examples of the 
identified mutations can be found in Supplementary Table S1. Tumors were classified as “wild-
type” (WT) if no mutation was found. 
DNA methylation assay, data processing and data analysis 
 Genomic DNA was bisulfite-converted using the EZ DNA Methylation Kit (Zymo 
Research, Orange, CA) following the manufacturer’s recommended procedures. Genome-wide 
promoter DNA methylation was determined using the Illumina Infinium HumanMethylation 
27K Platform (Illumina, San Diego, CA, USA) as described previously (24). This assay 
generates DNA methylation data for 27,578 CpG dinucleotides covering 14,473 genes. For each 
CpG site, methylation levels were quantified using β-values, which represent the proportion of 
methylation, calculated as M/(M+U), where M is the methylated probe intensity and U the 
unmethylated probe intensity. β-values range from 0 to 1, with 0 being completely unmethylated 
and 1 being completely methylated. We excluded probes designed for sequences on either the X 
or the Y chromosome (1085 or 7 probes, respectively), as well as 46 probes with missing value 
in at least one sample. The data used in these analyses have been deposited in NCBI’s Gene 
Expression Omnibus and are accessible through GEO Series accession number GSE72729 
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(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72729). The applied analysis 
workflow is schematically depicted in Supplementary Figure S1. 
Unsupervised hierarchical clustering was carried out using Cluster 3.0 software with 
“average linkage” (Pearson correlation, uncentered metrics). The clusters were subsequently 
visualized using Treeview (http://rana.stanford.edu/software). Principal component analysis 
(PCA) was performed using R CRAN version 2.15.3 (R, 2013). Differences in DNA 
methylation status among tumor groups (based on the driver mutations present in the samples) 
were tested using POMELO II, applying linear models (limma) (25). Only groups containing at 
least 5 tumors were considered. Each genetic class was compared to WT tumors, and with each 
of the other classes. To account for multiple hypothesis testing, p-values were adjusted using 
Benjamini and Hochberg’s false discovery rate (FDR) correction. We defined a probe to be 
hypomethylated or hypermethylated when it displayed a mean β-value difference (Δβ-value) < -
0.2 or > 0.2, respectively, calculated as mean difference among distinct tumor groups, and had a 
FDR<0.05. With the extracted lists of differentially methylated genes, we performed Venn 
diagram analyses using BioVenn (http://www.cmbi.ru.nl/cdd/biovenn/) and Pathway 
enrichment analysis using the functional annotation clustering tool implemented in DAVID 
Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/home.jsp).   
Since we had both mRNA (18) and miRNA expression (GEO Series accession number 
GSE72728 [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72728]) data for 33 and 
31 of the tumors used in this study, respectively, we aimed to identify genes whose expression 
is correlated with the methylation status of their corresponding promoter regions. Expression of 
all the available protein-coding genes identified as differentially methylated by tumor genotype 
(FDR < 0.05, |Δβ –value| > 0.2) was examined as previously described (12, 26). The integration 
of miRNA data required a genome-wide approach since there was only one microRNA gene 
promoter showing differential methylation. More specifically, there were 254 probes included 
on the methylation platform that mapped to promoters of 110 microRNA genes previously 
annotated by the manufacturer (24). To this number, we added 423 probes belonging to putative 
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promoter regions of 151 miRNAs identified using the PROmiRNA method (27). These 
additional probes and their corresponding miRNA genes are listed in Supplementary Table S2. 
Correlation was measured by the Spearman coefficient using R CRAN version 2.15.3 (R, 2013) 
and genes with a negative correlation coefficient and p-value<0.05 were considered 
significantly correlated. 
Confirmation of inverse correlation between methylation and expression in MTC cell lines 
To confirm the effect of DNA methylation on gene expression, MZ-CRC-1 cells at 60% 
of confluence were treated with 50 μg/ml 5-Aza-2-’Deoxycytidine (Sigma). This treatment was 
repeated every 48 hours over 6 days and then the cells were collected for RNA and DNA 
extraction.  
DNA methylation level assessment 
Bisulfite sequencing of MTC cell lines using the primers listed in Supplementary Table 
S3 was carried out according to protocols described elsewhere (12) in order to assess 
methylation level of the selected promoters (belonging to 3 protein-coding genes and 3 miRNA 
genes). 
qRT-PCR 
 For the assessment of expression of the selected protein-coding genes, one microgram 
of total RNA was reverse transcribed using Superscript II (Invitrogen) and an oligo dT14 primer 
following manufacturer’s instructions. The amounts of DKK4, MMP20 and PLCB2 mRNA 
were quantified by real-time PCR with QuantStudio 6 Flex Real-Time PCR system (Applied 
Biosystems), using primers designed to be specific for the three genes (Supplementary Table 
S3) and probes from the Universal ProbeLibrary Set, Human (Roche). Normalization was 
carried out with the internal standard β-actin (ACTB).  
 For miRNA gene expression quantification, 10 nanograms of total RNA were used for 
first-strand cDNA synthesis using the miRCURY LNA Universal RT miR PCR system 
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(Exiqon) and LNA miR-PCR primer/SYBR Green mix (Exiqon) was used for subsequent 
quantification of miR-10a, -30a and -200c according to the manufacturer’s recommendations. 
MiR-16 was selected as the reference gene for normalization. 
Negative controls were included in all PCR series and assays were carried out in 
triplicate. The ∆∆Ct method was used for the calculation of mRNA/miRNA content (28). 
Methylation status validation 
Three of the most differentially methylated probes, all showing negative correlation 
with expression of the corresponding protein-coding gene, and with biological functions 
potentially relevant to MTC were selected for validation. The technical validation of microarray 
results in a subset of the original discovery series (comprising 6 RETM918T, 6 RETC634, 3 RAS, 2 
“wild-type” tumors and 6 tumors bearing other RET mutations) was performed using bisulfite 
sequencing, as described elsewhere (12). The candidate functional methylation markers were 
then validated by pyrosequencing in 25 independent FFPE MTC samples (8 RETM918T, 4 
RETC634, 3 RAS and 10 “wild-type” tumors). The region of interest, including the CpG assessed 
by the Infinium array, was first amplified from the bisulfite-treated DNA by a set of primers 
designed using the PyroMark assay design software (version 2.0.01.15). Following PCR 
amplification, pyrosequencing was performed using PyroMark Q24 reagents, vacuum prep 
workstation, equipment and software (Qiagen). The primers used in these steps are listed in 
Supplementary Table S3.  
Immunohistochemical study 
Three paraffin-embedded TMAs and 7 complete sections were used for the evaluation 
of a JAK/Stat pathway effector pSTAT3 (Tyr705). Monoclonal antibody was obtained from 
Cell Signaling Technology (#9145). Two independent experienced pathologists (X.M.-G. and 
M.S.) evaluated the staining by visual examination under a microscope. Since each TMA 
included two different tumor cores from each case, immunohistochemical scoring was done 
after examining both samples. When the two cores gave inconsistent results, the complete 
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section of the corresponding tumor was evaluated. Samples were scored from 0 (no 
immunostaining) to 300 (intensive immunostaining) depending on both the intensity and 
extension of staining. 
Inhibitor treatment and cell proliferation assay  
For the study of proliferation inhibition by TKI and the inhibition of the 
phosphorylation of STAT3, Vandetanib (Seleckchem) and LLL12 (EMD Millipore) (29) were 
made up as a stock solution of 5 mM in dimethylsulfoxide (DMSO). MZ-CRC-1 and TT cells 
were plated in 200 μl of medium at concentrations of 2x104 cells per well. After 36 hours, cells 
were treated with increasing concentrations of the indicated compounds (0; 0.005; 0.05; 0.1; 0. 
5; 1; 2.5; 5 μM). A concentration of 0.1% DMSO was used in all conditions. This treatment was 
repeated every 4 days. Proliferation was measured at 10 days using a cell proliferation kit 
(WST-1 reagent, Roche). The concentration that led to 50% growth inhibition (IC50) was 
calculated using GraphPad Prim. All experiments were performed in triplicate. For the 
combinational treatment we also used the above-mentioned experimental scheme. A fixed 
concentration of 0.04 μM of LLL12 was combined with increasing concentrations of 
Vandetanib (0; 0.005; 0.05; 0.1; 0. 5; 1; 2.5; 5 μM). The suboptimal LLL12 concentration (0.04 
μM) used causes only 10% growth inhibition of MZ-CRC-1 cells. Additionally, for Western 
blot analysis, MZ-CRC-1 were treated with increasing concentrations of Vandetanib (0.01; 0.1; 
0.5 μM), 0.04 μM LLL12 and a combination of LLL12 and Vandetanib (0.04 μM and 0.1 μM, 
respectively) for 24 hours. Cells were then washed with ice-cold PBS, collected by scraping, 
and cell lysates were prepared using the above-mentioned protocol. The following primary 
antibodies were used for immunoblotting: p-ERK, pAKT, pSTAT3 and GAPDH (Cell 
Signaling; #9101, #4060, #9145 and #2118, respectively). Absolute band intensities of the 
indicated proteins were captured and quantified with the Image Lab software v4.1 (BioRad). 
GAPDH was used as loading control normalizer. Data were expressed in relative units using the 




Molecular characterization of the MTC discovery series 
 Among the tumors whose genome-wide DNA methylation levels were measured, 36 
(75%) harbored a RET mutation (13 carried the RETM918T mutation, 14 RETC634 and 9 less 
frequent RET mutations), and 6 (12.5%) tumors harbored a RAS mutation. The remaining 6 
tumors (12.5%) did not carry any alteration in the studied genes and were considered “wild-
type” (WT). The results of the mutational screening together with the main clinico-
histopathological characteristics of the samples are summarized in the Supplementary Table S4.  
MTC methylation profiles relate closely to RET mutational status 
 We identified 11,915 probes that were constitutively unmethylated (β-value <0.2) in all 
samples. According to DAVID functional enrichment analysis (30), the majority (97.5%) 
of these were located within CpG islands adjacent to house-keeping genes (Benjamini-
Hochberg adjusted p-value = 7.1x10-10). On the other hand, 179 probes were constitutively 
methylated (β-values>0.8 for all samples). Both constitutively unmethylated and methylated 
probes were excluded from further analyses. A PCA of the remaining 14,346 probes (belonging 
to 9,216 consensus coding sequences) did not identify any batch effects affecting the data 
(Supplementary Figure S2). 
 Unsupervised hierarchical analysis using the 851 probes with the variance >0.2 
identified two principal clusters that differed in their underlying genetics (Figure 1). Only two 
samples did not fall into either cluster. Interestingly, cluster B showed higher levels of 
methylation when compared to cluster A (p-value = 3.0x10-9), and was enriched with WT cases 
and those harboring the RETC634 mutation, while cluster A was composed mostly of RETM918T-
positive tumors (p-value<0.02). We did not observe any clear clustering of the RAS-mutated 
samples.  
 Supervised analysis according to driver mutation allowed us to identify a list of 
differentially methylated probes associated with specific mutations, which was especially long 
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for RETM918T-related tumors. These findings confirmed those from the unsupervised clustering, 
since in this group there were more hypomethylated probes (Figure 2A&2B, Supplementary 
Table S5). The protein-coding gene DKK4 (Dickkopf WNT Signaling Pathway Inhibitor 4), 
previously described to be up-regulated in RETM918T-related MTCs (18), was one of the genes 
affected by hypomethylation among RETM918T-positive carcinomas. Also consistent with the 
unsupervised clustering result, the lists of differentially methylated probes characteristic of the 
other genetic conditions (RETC634- and RAS-related tumors) when comparing to WT, were 
considerably shorter (Figure 2B). Nevertheless, hypomethylation of GAL was detected among 
RETC634-positive tumors when comparing to WT, and this event could cause the increased 
expression of this molecule reported elsewhere (18).  
Hypermethylation more frequently affected probes located within CpG islands (p-value 
0.0014) as well as those located near stem cell PolyComb Group target genes (p-value<0.0001). 
Hypomethylated probes, on the other hand, were enriched with CpGs that are heavily 
methylated in embryonic stem cells (p-value<0.0001) (Figure 2C). 
OMIC data integration reveals potentially functional DNA methylation changes in MTC  
The above findings indicated that some epigenetic changes can have a functional 
consequence, which encouraged us to systematically explore genes (protein- and miRNA-
coding) regulated by methylation at their promoters (see Supplementary Figure S1 for further 
details). mRNA expression data was available for > 91% of protein coding genes that were 
differentially methylated based on tumor genotype. A negative correlation between expression 
and methylation was observed for 5% of these (Supplementary Figure S3). PLCB2, DKK4, 
MMP20 were selected for further study since they have been previously described to have a role 
in the promoting tumor growth (18, 31-33). Moreover, a genome-wide assessment of 
methylation and miRNA expression of matching samples identified 5 miRNA genes (6.9%) 
showing negative correlation (Supplementary Figure S3). MiR-10a was also found as 
differentially methylated in the previous supervised analyses and was selected for further 
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studies. Two additional miRNA genes (miR-30a and -200c) showing negative correlation 
between expression and methylation, and a tendency towards differential methylation 
(FDR<0.15) in supervised clustering, were also studied further due to their biological function 
(21, 34, 35). As assessed by bisulfite sequencing, the levels of methylation of the 6 genes (3 
protein-coding and 3 microRNAs) differed between the two available MTC cell lines (Figure 
3A). Apart from two genes that were not expressed by either of the cell lines (MMP20 and miR-
30a), the expression of the other four genes confirmed the results of in silico predictions of 
inverse correlation between DNA methylation and gene expression (Figure 3B). Since MZ-
CRC-1 showed systematically higher levels of DNA methylation of these six loci, we treated it 
with the demethylating agent 5-Aza-2-’Deoxycytidine. A higher expression of all genes in the 
MZ-CRC-1 cell line was detected in the treated condition as compared to untreated one (Figure 
3C), further confirming the functional effect of these epigenetic changes. 
Validation of aberrant methylation of candidate oncogenes 
 CpGs from the promoters of 3 differentially methylated genes (DKK4, MMP20, 
PLCB2) were selected for validation. These genes also showed a negative correlation between 
DNA methylation levels and gene expression (Supplementary Figure S3). As depicted in Figure 
4, the results of bisulfite sequencing in a subset of the original series revealed a high correlation 
with the array-based measures (R2 ranging from 0.66 to 0.80). Moreover, we were able to 
replicate the findings by bisulfite pyrosequencing of an independent series of 25 FFPE MTCs 
(Figure 4), although the difference between the DNA methylation levels of the compared groups 
was smaller, probably because the DNA source was paraffin tissue. 
Multi-OMIC data and pathway enrichment analyses uncover JAK/Stat pathway 
involvement in RETM918T MTCs  
 Functional annotation clustering by DAVID (30) of the genes with aberrant methylation 
(Supplementary Figure S4) and by GSEA of differentially expressed genes (18) among 
RETM918T-positive carcinomas uncovered a significant enrichment for signaling pathways such 
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as cytokine-cytokine receptor interaction (p-value=1.5x10-7) and JAK/Stat (p-value=2.3x10-4). 
STAT3 is a JAK/Stat pathway effector and a putative downstream target of RET (36). Thus, we 
assessed by immunohistochemistry its active phosphorylated form (at Tyr705) in 101 MTC 
samples. RETM918T-related tumors were more frequently and intensively positively stained than 
the other genetic classes (p-value<0.02, Figure 5A) confirming activation of the JAK/Stat 
cascade and the in silico prediction. We aimed to exploit these differences to study in vitro the 
functional relevance of STAT3 activation in MTC. As revealed by proliferation assay, MZ-
CRC-1 cells were more sensitive to inhibition of STAT3 phosphorylation than TT cells 
(IC50(MZ-CRC-1) = 0.06 μM, IC50(TT) = 0.23 μM, Figure 5B). In fact, the RETM918T-mutated 
cell line showed a higher sensitivity to this treatment than to the standard of care, TKI 
Vandetanib (IC50(MZ-CRC-1) = 0.62 μM, Figure 5B).  
 Since STAT3 is a downstream point of convergence for many growth factor pathways, 
synergy may be expected when combined with other inhibitors (37). A suboptimal dose of 
pSTAT3 inhibitor, when combined with Vandetanib, apparently showed a synergistic effect on 
cell growth inhibition of RETM918T-positive cells (Figure 5C). Moreover, treatment with 
Vandetanib produced a dose-dependent inhibition of pSTAT3 in MZ-CRC-1, and suboptimal 
combinational treatment of the two drugs (0.04 μM LLL12 with 0.1 μM Vandetanib) 
potentiated the inhibitory effect on both canonical (pERK, pAKT) and non-canonical (pSTAT3) 





 The current genomic era offers great opportunities to answer many clinically relevant 
questions concerning various types of cancer through comprehensive and integrative analyses of 
OMIC data. Some cancer types are being neglected by these efforts, generally due to their low 
prevalence, and thus small overall public health impact. Medullary thyroid carcinoma is one of 
the least prevalent subtypes of thyroid cancer, but is responsible for a large proportion of 
thyroid cancer-related deaths (38), mainly because treatment with cytotoxic drugs and/or 
standard radiotherapy has been proven to be ineffective (39).  
Using the largest cohort of MTC samples reported to date, we have applied a multilayer 
OMIC data integration focused on the effects of DNA methylation in the etiology of this tumor. 
The current work is the first to report not only that underlying genetics relates closely to 
genome-wide DNA methylation fingerprints, but also that the aberrant methylation events affect 
specific genomic loci (for example, PolyComb targets) pointing to the existence of an 
epigenetic progenitor cell signature in MTC (40). Furthermore, we identify both protein-coding 
and microRNA genes, the expression of which is negatively correlated with the methylation 
status of their promoters, and we confirm some of these findings in MTC cell lines. We propose 
promoter methylation of MMP20, DKK4 and PLCB2 as functional epigenetic markers of MTC 
genetic classes. The integrative approach allowed us to uncover the involvement of the 
JAK/Stat pathway in RETM918T-related MTCs, which apparently sustains the proliferative 
features of the MTC cell model for this genetic class.   
DNA methylation is traditionally believed to be a regulator of gene expression. In the 
case of protein-coding genes, the classical view of the negative effect of methylation on 
expression is being challenged by recent technical advances. Many cancer-orientated studies, 
including the current one, report a surprisingly low percentage of genes for which this inverse 
relationship applies (26). The situation with microRNAs is even more complex, given the 
difficulties with identifying their promoter regions (41). Recently, a methodology became 
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available that recognizes putative promoter regions of miRNAs using both sequence- and 
histone-based techniques (27). By integrating this strategy in our analysis, we were able to 
identify CpGs belonging to additional putative miRNA promoters included on the 27K array. 
The overall portion of miRNA genes for which a negative correlation between methylation and 
expression was observed was similar to that for protein-coding genes. Nevertheless, for the 
majority of the genes selected for validation of the inverse correlation between expression and 
methylation in MTC cell lines, we were able to functionally confirm the in silico predictions. 
One of these genes, DKK4, has previously been linked to MTC pathogenesis (18), and here we 
propose aberrant methylation as the regulatory mechanism responsible for its over-expression in 
RETM918T-related tumors. On the other hand, PLCB2 plays a role in multiple transmembrane 
signal transduction pathways involving inositol lipid metabolism. In cancer, its over-expression 
has been associated with mitosis promotion, migration and poor outcome (31, 42). Our finding 
of hypomethylation in the RETM918T-positive tumor samples, which was negatively associated 
with increased PLCB2 expression, is consistent with this gene having a cancer-promoting role. 
Even though the prognostic utility of MMP20, a member of the family of metalloproteinases, 
has already been demonstrated in cancer (32), we did not detect its expression in the studied cell 
lines. Nevertheless, its validation in an independent series of MTC carcinomas confirms its 
potential utility as a methylation marker of RETM918T-related tumors. 
 Regarding miRNA genes, the expression of miR-200c has been recently described as 
causative of the metastatic potential of human MTCs (21). Interestingly, according to our results 
in MTC cell lines, the aberrant methylation of the putative promoter of miR-200c could underlie 
its differential expression among patients with distinct disease outcomes. MiR-10a mostly 
exerts an oncogenic effect (43, 44) and we found little DNA methylation of its promoter in both 
MTC cell lines. There is evidence from hepatocellular carcinoma that miR-10a is negatively 
regulated by DNA methylation (45), which was further validated by our findings. MiR-30a 
warrants further study due to its tumor-suppressive features (34, 35). PROM1, a cancer stem 
cell marker found over-expressed in RETM918T-positive tumors (18), is one of its predicted 
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targets, according to targetscan tool (http://www.targetscan.org/). Our findings indicate that a 
hypermethylation-driven down-regulation of miR-30a could lead to an up-regulation of its 
target PROM1. 
Our integrated analysis pointed to the involvement of signaling networks such as 
cytokine-cytokine interaction and JAK/Stat in RETM918T tumors. These pathways have 
previously been related to malignant tumor behavior, which is consistent with the observation 
that these MTC patients have the worst clinical outcomes (5). The genetic class-specific 
implication of JAK/Stat pathways was confirmed by IHC in a large number of human tumors. 
This is in line with previous in vitro findings from 293T cells transfected with wild-type RET or 
RETM918T, where only the latter induced constitutive phosphorylation of STAT3. On top of that, 
RETM918T was far more efficient in recruiting STAT3 protein than both RETC634 and wild-type 
RET in vitro (46). Constitutive activation of STAT3 has been reported at high frequency in 
large numbers of malignant cell lines, in vivo animal models and human tumors (reviewed in 
(37)). In general, activation of STAT3 is associated with a worse prognosis due to its role in 
uncontrollable proliferation and modulation of microenvironment (reviewed in (47)). Thus, 
STAT3 is a very attractive molecule for targeted therapies (reviewed in (48)). Indeed, while no 
drug has shown promising results in clinical trials (49), it has been suggested that inhibition of 
STAT3 signaling in combination with other therapies (targeted therapies or radiotherapy) could 
lead to clinical benefit (50). We found that low doses of the inhibitor of pSTAT3 increased the 
sensitivity of MTC cells to Vandetanib treatment. This could have an important impact on the 
management of MTC patients, since Vandetanib treatment leads to frequent toxicities, which 
require dose reductions or even discontinuation (8). 
 In summary, this comprehensive integrative genomic study performed using the largest 
cohort of MTC samples reported to date, provides insights into the involvement of DNA 
methylation in the etiology of this disease. We confirmed the regulatory role of DNA 
methylation for DKK4, PLCB2, MMP20, miR-10a, miR-30a and miR-200c using MZ-CRC-1 
and TT cell lines. Moreover, hypomethylation may induce activation of key pathways related to 
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the malignant behavior of RETM918T-related MTCs. Inhibition of one of these – the STAT3 
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TABLE AND FIGURE LEGENDS 
Figure 1. Methylome of the discovery series. Unsupervised hierarchical cluster analysis of 48 
medullary tumors divided the sample set into 2 main clusters. “Cluster A” was composed 
mostly of RETM918T-related samples. “Cluster B” included the majority of RETC634- and wild-
type cases. Color codes used are as follows: red = RETM918T mutation, black = RETC634 mutation, 
yellow = RAS mutation, transparent = other RET mutation, green = wild type. 
Figure 2. Identification of differentially methylated probes. A) Volcano plots, from each of 
the supervised analysis carried out, identifying differentially hypomethylated (green) and 
hypermethylated (red) probes, defined based on FDR<0.05 and |Δβ-value| ≥ 0.2. B) Venn 
diagram showing the overlap between the identified mutation-specific hyper- and hypo-
methylated probes from comparisons with WT tumors. C) Number of probes hypermethylated 
and hypomethylated, by location with respect to: CpG islands; gene targeted by PolyComb 
Repressive Complex; loci that are heavily methylated in embryonic stem cells. 
Figure 3. Confirmation of negative correlation between methylation and gene expression 
in MZ-CRC-1 and TT cell lines. A) DNA methylation levels of promoter CpGs of DKK4, 
PLCB2, MMP20, miR-10a, -200c and -30a as measured by bisulfite sequencing. B) Expression 
of DKK4, PLCB2, MMP20, miR-10a, -200c and -30a shows an opposite trend as compared to 
the DNA methylation levels of the genes, confirming in silico results. C) 5-aza-2′-deoxycytidine 
(5AdC) treatment causes the reactivation of DKK4, PLCB2, MMP20, miR-10a, -200c and -30a 
expression in the MZ-CRC-1 cell line. 
Figure 4 Validation of selected loci. Three CpGs from promoter regions of MMP20, PLCB2 
and DKK4 were selected for validation. In the left panel, results from the discovery series are 
represented. In the middle panel, correlation between the results from Illumina Infinium 
HumanMethylation 27K Platform and bisulfite sequencing for selected loci is shown. Bisulfite 
sequencing was performed in a subset of samples included in the discovery series (6 RETM918T, 6 
RETC634, 3 RAS, 2 “wild-type” tumors and 6 tumors bearing other RET mutations). In the right 
25 
 
panel, results of bisulfite pyrosequencing of 25 independent MTC samples (8 RETM918T, 4 
RETC634, 3 RAS and 10 “wild-type” tumors) are depicted.  
Figure 5. STAT3 signaling in RETM918T-related MTC. A) Immunohistochemical study of 101 
MTC samples. Staining was scored according to both extent and intensity. Each point represents 
one tumor staining result; bars represent the median value in a given genetic class. The most 
intense positive staining was detected among RETM918T-positive MTCs (p-value=0.014). B) 
Effects of TKI and inhibitor of phosphorylation of STAT3 on MTC cell proliferation. MZ-
CRC-1 and TT cell lines were treated with increasing concentrations of Vandetanib (Tyrosine 
Kinase Inhibitor) or LLL12 (Inhibitor of phosphorylation of STAT3) for 10 days. At day 10 the 
proliferation was assessed using WST-1 reagent. Average values of triplicated experiments are 
presented with error bars representing the standard deviation (SD). Concentration (listed in μM) 
leading to 50% of growth inhibition (IC50) and the 95% confidence interval (95% CI) were 
determined using GraphPad Prim. C) LLL12 sensitized MZ-CRC-1 cells to Vandetanib 
treatment. MZ-CRC-1 cells were treated with a fixed sub-IC50 concentration of LLL12 (0.04 
μM) combined with increasing concentrations of Vandetanib and the results were compared to 
Vandetanib and LLL12 monotherapy. The average values of triplicated experiments with the 
corresponding SD clearly showed an apparently synergistic effect of the two inhibitors. D) 
Western blot analysis of canonical (AKT, ERK) and non-canonical (STAT3) targets of RET 
signaling. Cell lysates from untreated MZ-CRC-1 cells, and those treated with increasing 
concentrations of Vandetanib (0.01; 0.1; 0.5 μM), 0.04 μM LLL12 and a combination of LLL12 
and Vandetanib (0.04 μM and 0.1 μM, respectively) were subjected to Western blot analyses for 
pERK, pAKT, pSTAT3 and GAPDH (loading control). Combined treatment with sub-IC50 

























































CpG islands PolyComb targets Methylated loci in ESC 
















VANDETANIB IC50 (μM) 95% CI (μM) 
MZ-CRC-1 0.62 0.48-0.79 
TT 0.09 0.05-0.16 
LLL12 IC50(μM) 95% CI (μM) 
MZ-CRC-1 0.06 0.05-0.08 







1 1.38 0.72 0.17 0.69 0.66 
1 0.96 0.56 0.19 0.97 0.42 
1 1.43 0.78 0.32 0.67 0.11 
p-ERK 1/2 (Tyr202/Tyr204) 
